Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10179140 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
US9603860 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
US10603281 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
US10849857 | EXELTIS USA INC | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Jun, 2031
(7 years from now) | |
US10987364 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
US11123299 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
US11478487 | EXELTIS USA INC | NA |
Jun, 2031
(7 years from now) | |
US11413249 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
US11291633 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
US11351122 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
US11291632 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
US11439598 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) | |
US11504334 | EXELTIS USA INC | Synthetic progestogens and pharmaceutical compositions comprising the same |
Jun, 2031
(7 years from now) |
Slynd is owned by Exeltis Usa Inc.
Slynd contains Drospirenone.
Slynd has a total of 13 drug patents out of which 0 drug patents have expired.
Slynd was authorised for market use on 23 May, 2019.
Slynd is available in tablet;oral dosage forms.
Slynd can be used as prevention of pregnancy in females of reproductive age.
The generics of Slynd are possible to be released after 28 June, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product (NP) | May 23, 2022 |
Drugs and Companies using DROSPIRENONE ingredient
Market Authorisation Date: 23 May, 2019
Treatment: Prevention of pregnancy in females of reproductive age
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic